Skip to main content
. 2017 Nov 21;23(43):7716–7726. doi: 10.3748/wjg.v23.i43.7716

Table 2.

Clinical characteristics of patients with Wilson’s disease in Hong Kong [n = 211, n (%)]

Variables Clinical characteristics
Age 27.9 (18.2-39.7)
Male 104 (49.3)
Drug 193 (91.5)
D-penicillamine1 129 (61.6)
Trientine2 22 (10.4)
Zinc 42 (19.9)
Hepatic disease 176 (83.4)
Cirrhosis 38 (21.6)
Cirrhotic complications 19 (10.8)
Ascites 10 (5.7)
Spontaneous bacterial peritonitis 5 (2.8)
Esophageal varices 10 (5.7)
Gastric varices 5 (2.8)
Hepatic encephalopathy 8 (4.5)
Hepatocellular carcinoma 3 (1.7)
Neurological disease 30 (14.2)
Parkinsonism 15 (50.0)
Tremor 3 (10.0)
Dystonia 4 (13.3)
Tics 1 (3.3)
Dementia 2 (6.7)
Seizure 7 (23.3)
Psychiatric disease 24 (11.4)
Depression 9 (37.5)
Anxiety 2 (8.3)
Bipolar disorder 4 (16.7)
Organic affective syndrome 3 (12.5)
Psychosis 4 (16.7)
Personality disorder 3 (12.5)
Suicide 4 (16.7)
Concomitant hepatic and neurological/psychiatric diseases 21 (10.0)
Non-immune hemolytic anemia 8 (3.8)
Viral hepatitis 7 (3.3)
Chronic hepatitis B infection 5 (71.4)
Chronic hepatitis C infection 2 (28.6)
Metabolic factors 17 (8.1)
Diabetes mellitus 3 (17.6)
Hypertension 7 (41.2)
Dyslipidemia 4 (23.5)
Obesity 4 (23.5)
Alcoholism 4 (23.5)
Liver transplantation 24 (11.3)
Death 26 (12.3)
1

Twenty four patients had concomitant zinc therapy during the initial treatment phase or maintenance phase;

2

Eight patients had concomitant zinc therapy during the initial treatment phase or maintenance phase. Age was expressed as median (years) with interquartile range. Categorical variables were expressed as n (%).